Research Article

Evaluation of Antinociceptive Activity of Ethanol Extract of Leaves of Adenanthera pavonina

Md. Moniruzzaman, Ambia Khatun, and Mohammad Zafar Imam

1 College of Pharmacy, Dongguk University, Goyang 410-820, Republic of Korea
2 Department of Pharmacy, Stamford University Bangladesh, 51 Siddeswari Road, Dhaka 1217, Bangladesh

Correspondence should be addressed to Mohammad Zafar Imam; zafarimam@gmail.com

Received 6 March 2015; Accepted 16 July 2015

Adenanthera pavonina is a deciduous tree commonly used in the traditional medicine to treat inflammation and rheumatism. The aim of this study was to evaluate the antinociceptive activity of ethanol extract of leaves of A. pavonina (EEAP). EEAP was investigated using various nociceptive models induced thermally or chemically in mice including hot plate and tail immersion test, acetic acid-induced writhing, and glutamate- and formalin-induced licking tests at the doses of 50, 100, and 200 mg/kg body weight (p.o.). In addition, to assess the possible mechanisms, involvement of opioid system was verified using naloxone (2 mg/kg) and cyclic guanosine monophosphate (cGMP) signaling pathway by methylene blue (MB; 20 mg/kg). The results have demonstrated that EEAP produced a significant and dose-dependent increment in the hot plate latency and tail withdrawal time. It also reduced the number of abdominal constrictions and paw lickings induced by acetic acid and glutamate respectively. EEAP inhibited the nociceptive responses in both phases of formalin test. Besides, the reversal effects of naloxone indicated the association of opioid receptors on the exertion of EEAP action centrally. Moreover, the enhancement of writhing inhibitory activity by MB suggests the possible involvement of cGMP pathway in EEAP-mediated antinociception. These results prove the antinociceptive activity of the leaves of A. pavonina and support the traditional use of this plant.

1. Introduction

Inflammation is one of the most common physiological events that lead to chronic pain in response to tissue injury. It causes a consecutive change in several cellular components including neurotrophic factors, neuropeptides, prostanoids, and kinins which are able to conduct and amplify the nociceptive perception [1]. The changes in these cellular components have also been reported to generate and liberate different inflammatory mediators such as cytokines and chemokines by the immune or central nervous system cells, which cause the sensitization of the peripheral nociceptors [2]. However, the long term use of the currently available therapies to combat pain and inflammation tends to have serious side effects and low efficacy, especially for chronic diseases [3]. Thus, the development of agents that can control pain and inflammation with fewer side effects has been suggested to be a promising therapeutic approach to treat different painful conditions.
octacosanol, dulcitol, glucosides of β-sitosterol, and stigmas-
sterol have also been reported to be present in the leaves of
this plant [7]. Pharmacological studies of the plant showed
that the seeds of this plant possess anticonvulsant and central
nervous system depressant, analgesic, and anti-inflammatory
activity [8, 9]. But, so far, there is no report demonstrating
the antinociceptive activity of the leaves of A. pavonina
which prompted us to design our present study to evaluate
the effectiveness of ethanol extract of this plant leaves in
different nociceptive models and investigate the possible
mechanism(s) involved in this effect.

2. Materials and Methods

2.1. Plant Material and Extraction. A. pavonina leaves were
collected from Dhaka, Bangladesh, in January 2013. The
samples were then recognized by Bushra Khan, Principal
Scientific Officer of Bangladesh National Herbarium, Mirpur,
Dhaka, Bangladesh. A voucher specimen (DACB: 37941)
has been deposited to the Herbarium for further reference.
Powdered dried leaves (250 g) were macerated with 350 mL
of ethanol and subjected to occasional stirring at 25 ± 2°C
for 3 days. Then the extract was collected and the solvent
was completely removed by rotary evaporator. 11.52 g extract
(yield 4.61% w/w) was obtained which was then used for all
of the experimental studies.

2.2. Phytochemical Analyses. The crude extract of A. pavon-
ina was assessed qualitatively to detect the presence of
different phytochemicals such as carbohydrates, saponins,
flavonoids, tannins, alkaloids, glycosides, glucosides, reduc-
sing sugars, proteins, gums, and steroids following standard
procedures [4].

2.3. Chemicals and Drugs. Morphine sulphate was obtained
from Gonoshasthayya Pharmaceuticals Ltd. (Savar, Bangla-
desh) and diclofenac sodium was obtained from Square
Pharmaceuticals Ltd. (Dhaka, Bangladesh). Naloxone was
purchased from Hameln Pharmaceuticals GmbH (Hameln,
Germany). Acetic acid, L-glutamic acid, formalin, methylene
blue, ethanol, and 99% dimethyl sulfoxide (DMSO) were
procured from Merck (Darmstadt, Germany).

2.4. Animals. In the entire set of experiment, Swiss albino
mice (20–25 g) of either sex were used. The animals were
purchased from Animal Resources Branch of the International
Center for Diarrheal Disease Research, Bangladesh (icddrb).
The animals were kept in standard laboratory conditions
(relative humidity: 55–60%; room temperature: 25 ± 2°C; 12 h
light/12 h dark cycle) and were provided with standard diet
(icddrb formulated) and water ad libitum. The animals were
kept in the laboratory for 14 days prior to the experiments so
they can acclimatize to the laboratory environment. The animals
were kept fasting overnight before the experiments to avoid
any possible food-extract/drug interaction. All the experi-
mental animals were treated following the “Ethical Principles
and Guidelines for Scientific Experiments on Animals” (1995)
formulated by The Swiss Academy of Medical Sciences
and the Swiss Academy of Sciences. All experimental steps
conducted in this study were permitted by the Institutional
Ethics Committee of Stamford University Bangladesh.

2.5. Drugs and Treatments. Morphine sulphate (5 mg/kg)
was employed in hot plate, tail immersion, and formalin
tests and diclofenac sodium (10 mg/kg) was used in writhing
and glutamate-induced licking tests as standard drug. These
drugs were administered intraperitoneally (i.p.) 15 min before
the induction of nociception. In both chemical- and heat-
induced pain models, EEAP was administered orally for 30 min
prior to the experiments at the doses of 50, 100, and
200 mg/kg, where the animals in control group received
DMSO (vehicle; 0.1 mL/mouse, p.o.).

2.6. Acute Toxicity Test. Animals were randomly assigned
to different groups containing 5 mice in each group. EEAP
was administered to the animals orally at the doses of 500,
1000, and 2000 mg/kg. The mice were allowed food and
water ad libitum and all animals were observed for abnormal
behaviors, allergic symptoms, and mortality for the next 72 h
[10].

2.7. Antinociceptive Analysis

2.7.1. Hot Plate Test. The hot plate test was performed
according to previously described method [11]. The animals
were selected 24 h prior to the experiment according to
their responses such as forepaw licking, paw withdrawal, or
jumping within 15 s of thermal stress. Then they were treated
with EEAP or morphine as mentioned above and placed on
Eddy’s hot plate (Kshitij Innovations, Haryana, India) kept at
a temperature of 50 ± 0.5°C. A cut-off time was maintained
for 20 s to avoid paw tissue damage of the animals. The
latency was then recorded following their behavior in the hot
plate at 30, 60, 90, and 120 min after the treatment. Finally,
the percentage of the maximal possible effect (%MPE) was
calculated using the following equation:

\[
\text{%MPE} = \left( \frac{(\text{Postdrug latency}) - (\text{Predrug latency})}{(\text{Cut-off time}) - (\text{Predrug latency})} \right) \times 100.
\]\n
2.7.2. Tail Immersion Test. This experiment was done based
on the previous observation demonstrating that morphine
like analgesics prolong the tail withdrawal latency from hot
water in mice [12]. Mice that showed tail withdrawal time
between 1.5 and 3.5 s were selected for this experiment and
the pretreatment latency was recorded. Then the animals
were pretreated with morphine or EEAP and one to two cm
of their tail was immersed in the warm water with constant
temperature of 54 ± 0.5°C. The time between tail submersion
and tail deflection was recorded at 30, 60, 90, and 120 min
after the treatment with standard drug or extract. A cut-off
time of 20 s was maintained to avoid tail tissue damage in the
animals. Then %MPE was calculated using the same formula
employed in hot plate test.
2.7.3. Acetic Acid-Induced Writhing Test. The animals were treated with standard drug or EEAP or vehicle and then the writhing was induced with injection of 0.6% acetic acid 15 min after drug or 30 min after EEAP administration. Five minutes after acetic acid administration, the mice were observed and the writhing number was counted for 30 min as described previously [13]. The incidences of contractions of the abdomen, elongation of the body, twisting of the trunk, and/or pelvis ending were considered as complete writhing.

2.7.4. Glutamate-Induced Nociception. 10 μM of glutamate was injected into the ventral surface of the right hind paw of the mice 30 min after EEAP treatment or 15 min after injection of diclofenac sodium. The animals were then observed for 15 min following glutamate injection and the licking number of its injected paw was recorded as an indication of nociception [14].

2.7.5. Formalin-Induced Nociception. 60 min after EEAP or 15 min after treatment with morphine, 20 μL of 2.5% formalin solution was injected into the subplantar region of the right hind paw of the mice. The licking or biting of the injected paw was then recorded from 0–5 min as neurogenic phase and 15–30 min for inflammatory phase [15, 16].

2.8. Analysis of the Possible Mechanism of Action of EEAP

2.8.1. Involvement of Opioid System. The possible involvement of the opioid receptors system in the antinociceptive effect of EEAP was examined by injecting naloxone hydrochloride (2 mg/kg i.p.), a nonspecific opioid receptor antagonist, 15 min prior to the administration of either morphine or EEAP. The hot plate and tail immersion latencies were sequentially measured at 30, 60, 90, and 120 min after treatment of morphine or EEAP [17].

2.8.2. Involvement of Cyclic Guanosine Monophosphate (cGMP) Pathway. To validate the possible participation of cGMP pathway in the antinociceptive action caused by EEAP, the mice were pretreated with a nonspecific inhibitor of NO/guanylyl cyclase (MB) at the dose of 20 mg/kg, i.p. 15 min before the administration of EEAP. Then the nociceptive responses against 0.6% acetic acid injection were observed for 30 min, starting from 5 min after injection. The numbers of abdominal writhing were considered as the scoring of pain behavior [18].

2.9. Statistical Analysis. The results are expressed as mean ± SEM. The statistical analysis was performed by one-way analysis of variance (ANOVA) followed by Dunnett’s or Bonferroni’s post hoc test as appropriate, using SPSS 11.5 software. Differences between groups were considered significant at p < 0.05.

3. Results

3.1. Phytochemical Screening. Preliminary phytochemical screening of the crude ethanol extract of the leaves of A. pavonina confirmed the presence of alkaloids, carbohydrates, proteins, flavonoids, glycosides, saponins, steroids, and tannins.

3.2. Acute Toxicity Test. The oral administration of EEAP at the doses of 500–2000 mg/kg did not produce any abnormal behavior of the animals. The same dose of EEAP also did not cause any allergic manifestation or mortality during the observation period of 72 h after administration. Therefore, it is possible that EEAP may not be toxic at all the doses used in this study up to 2000 mg/kg.

3.3. Hot Plate Test. As shown in Table 1, all the doses of EEAP exhibited antinociceptive activity but with varying degree in the hot plate algesiometer-based evaluation of nociception in mice. Oral administration of EEAP significantly increased the latency period at 100 and 200 mg/kg (p < 0.01) doses at 60–120 min observation period. As expected, morphine at 5 mg/kg demonstrated a significant antinociceptive effect compared to control (p < 0.001). Naloxone at 2 mg/kg dose significantly reversed the antinociceptive effect of morphine (p < 0.001) or EEAP at 100 and 200 mg/kg doses (p < 0.05).

3.4. Tail Immersion Test. In the tail immersion test, EEAP showed marked antinociceptive activity in a dose-dependent manner (Table 2). More specifically, at 60 min after oral administration, EEAP at both 100 and 200 mg/kg doses significantly delayed (p < 0.01) the reaction time in response to a nociceptive stimulus. Morphine, the reference drug, also exhibited strong antinociceptive activity where naloxone significantly attenuated the antinociceptive effect of morphine (p < 0.01) as well as EEAP at 100 and 200 mg/kg doses (p < 0.05), in parallel with the findings of the hot plate test.

3.5. Acetic Acid-Induced Writhing Test. The extent of writhing in mice induced by administration of 0.6% of acetic acid was significantly suppressed (p < 0.01) by all the doses of EEAP (Figure 1). This suppression is comparable to the writhing inhibitory effect of diclofenac sodium (74.19%) used as a reference drug.

3.6. Glutamate-Induced Nociception. The oral administration of EEAP (50, 100, and 200 mg/kg) caused a significant inhibition of the glutamate-induced nociception in a dose-dependent manner (Figure 2). The reference drug diclofenac sodium also produced significant antinociceptive effect (p < 0.001).

3.7. Formalin-Induced Nociception. In both phases of the formalin test, EEAP caused a dose-dependent inhibition of the licking number induced by formalin (Figure 3). The effect is statistically significant (p < 0.001) with all of the experimental doses, where 60.87% of licking inhibition in the first phase and 98.22% inhibition in second phase were observed with the dose of 200 mg/kg of EEAP.
Table 1: Antinociceptive effect of ethanol extract of leaves of A. pavonina and morphine and reversal effect of naloxone in hot plate test.

| Treatment (mg/Kg) | Pretreatment | 30 min | 60 min | 90 min | 120 min |
|------------------|--------------|--------|--------|--------|---------|
| Control (0.1 mL/mouse) | 6.05 ± 0.19 | 6.24 ± 0.39 | 6.82 ± 0.21 | 7.46 ± 0.16 | 7.86 ± 0.28 |
| Morphine (5) | 6.21 ± 0.19 | 12.84 ± 0.84* (48.09) | 15.03 ± 1.21* (63.99) | 15.59 ± 0.61* (68.01) | 15.83 ± 1.31* (69.75) |
| EEAP (50) | 5.72 ± 0.74 | 7.84 ± 0.63 (14.90) | 9.11 ± 0.65 (23.77) | 9.97 ± 0.63 (29.81) | 10.40 ± 0.31 (32.78) |
| EEAP (100) | 6.31 ± 0.34 | 8.22 ± 0.41 (13.96) | 10.58 ± 0.32** (31.17) | 11.45 ± 1.00** (37.53) | 11.58 ± 1.13 (38.45) |
| EEAP (200) | 5.83 ± 0.66 | 8.85 ± 0.60 (21.35) | 11.94 ± 0.10** (43.11) | 12.96 ± 0.81** (50.32) | 14.31 ± 0.52** (59.84) |
| NLX (2) + control (0.1 mL/mouse) | 5.85 ± 0.43 | 5.92 ± 0.30 | 6.08 ± 0.33 | 6.32 ± 0.34 | 7.06 ± 0.22 |
| NLX (2) + morphine (5) | 6.01 ± 0.55 | 6.79 ± 0.72a (5.57) | 7.94 ± 0.56a (13.81) | 8.39 ± 0.58a (17.01) | 10.27 ± 1.48a (30.47) |
| NLX (2) + EEAP (50) | 5.92 ± 0.32 | 6.84 ± 0.37 (6.57) | 7.10 ± 0.33 (8.44) | 8.34 ± 0.84 (17.24) | 8.81 ± 0.57 (20.53) |
| NLX (2) + EEAP (100) | 5.89 ± 0.42 | 7.35 ± 0.44 (10.35) | 7.55 ± 0.32a (11.76) | 8.46 ± 0.56 (18.23) | 9.08 ± 0.56 (22.58) |
| NLX (2) + EEAP (200) | 6.03 ± 0.42 | 7.54 ± 0.59 (10.82) | 8.60 ± 0.32a (18.40) | 9.45 ± 0.50a (24.52) | 10.95 ± 0.69 (35.26) |

Each value is presented as the mean ± SEM (n = 5); EEAP = ethanol extract of A. pavonina; NLX = naloxone; *p < 0.001 compared with the control group (Dunnett's test); **p < 0.01 compared with the control group (Dunnett's test); †p < 0.001 compared with the morphine group (Bonferroni's test); ‡p < 0.05 compared with the EEAP 100 mg/kg group (Bonferroni's test); §p < 0.05 compared with the EEAP 200 mg/kg group (Bonferroni's test).

Table 2: Antinociceptive effect of ethanol extract of leaves of A. pavonina and morphine and reversal effect of naloxone in tail immersion test.

| Treatment (mg/Kg) | Pretreatment | 30 min | 60 min | 90 min | 120 min |
|------------------|--------------|--------|--------|--------|---------|
| Control (0.1 mL/mouse) | 1.88 ± 0.22 | 2.16 ± 0.39 | 2.38 ± 0.15 | 2.56 ± 0.18 | 2.74 ± 0.18 |
| Morphine (5) | 1.74 ± 0.05 | 3.12 ± 0.30 (75.8) | 3.93 ± 0.21a (11.98) | 4.37 ± 0.27a (14.43) | 4.48 ± 0.04* (15.01) |
| EEAP (50) | 1.75 ± 0.11 | 2.33 ± 0.14 (3.21) | 2.72 ± 0.22** (5.35) | 2.96 ± 0.27** (6.64) | 3.16 ± 0.16 (7.77) |
| EEAP (100) | 1.94 ± 0.32 | 2.80 ± 0.15 (4.76) | 3.28 ± 0.11** (7.41) | 3.63 ± 0.13** (9.33) | 3.78 ± 0.41** (10.15) |
| EEAP (200) | 1.99 ± 0.20 | 2.95 ± 0.19 (5.36) | 3.58 ± 0.17 (8.87) | 4.09 ± 0.19 (11.67) | 4.02 ± 0.22 (11.27) |
| NLX (2) + control (0.1 mL/mouse) | 1.79 ± 0.05 | 1.99 ± 0.22 | 1.97 ± 0.14 | 2.11 ± 0.23 | 2.23 ± 0.22 |
| NLX (2) + morphine (5) | 1.65 ± 0.10 | 2.07 ± 0.17 (2.29) | 2.78 ± 0.25a (6.17) | 2.91 ± 0.20a (6.87) | 3.24 ± 0.21a (8.69) |
| NLX (2) + EEAP (50) | 1.71 ± 0.16 | 2.14 ± 0.15 (2.36) | 2.30 ± 0.16 (3.25) | 2.46 ± 0.16 (4.10) | 2.97 ± 0.27 (6.88) |
| NLX (2) + EEAP (100) | 1.89 ± 0.35 | 2.31 ± 0.14 (2.31) | 2.45 ± 0.13 (3.09) | 2.54 ± 0.18b (3.57) | 3.20 ± 0.19 (7.21) |
| NLX (2) + EEAP (200) | 1.65 ± 0.25 | 2.50 ± 0.28 (4.64) | 2.66 ± 0.17a (5.50) | 3.08 ± 0.29 (7.80) | 3.31 ± 0.18 (9.05) |

Each value is presented as the mean ± SEM (n = 5); EEAP = ethanol extract of A. pavonina; NLX = naloxone; *p < 0.001 compared with the control group (Dunnett's test); **p < 0.01 compared with the control group (Dunnett's test); †p < 0.01 compared with the morphine group (Bonferroni's test); ‡p < 0.05 compared with the EEAP 100 mg/kg group (Bonferroni's test); §p < 0.05 compared with the EEAP 200 mg/kg group (Bonferroni's test).

3.8. Involvement of Cyclic Guanosine Monophosphate (cGMP) Pathway. The present study evaluated the impact of MB treatments (20 mg/kg) on the antinociceptive activity of EEAP at 50, 100, and 200 mg/kg doses. Treatment with EEAP or MB alone significantly inhibited acetic acid-induced abdominal writhing (Table 3). The extent of EEAP-induced antinociception effect was significantly (p < 0.05) enhanced when EEAP was cotreated with MB.

4. Discussion

This study evaluated the effects of the crude ethanol extract of A. pavonina, using several in vivo models of nociception in rodents. The results demonstrated that oral administration of EEAP significantly reduced the nociceptive responses in a dose-dependent manner.

Hot plate and tail immersion tests on mice were used to evaluate the effect of extract against thermal stimuli. These tests are widely used to investigate centrally acting analgesic drugs which delays the response against heat-induced pain thresholds [19, 20]. More specifically, the tail immersion and the hot plate tests serve as a popular tool to monitor the spinal and supraspinal reflexes, respectively [21]. Further elaborate studies have revealed that μ2- and δ-opioid receptors are involved in spinal mechanism, while μ1/μ2-opioid receptors are speculated to be primarily associated with supraspinal analgesia [22, 23]. In this study, EEAP at both 100 and 200 mg/kg doses significantly increased the time latency in hot plate test revealing the central antinociceptive activity of EEAP. This effect was parallel to the impact of EEAP in the tail immersion test. To further investigate possible antinociceptive mechanism(s) of EEAP action, the effect of naloxone, a nonselective opioid receptor antagonist, was examined against the antinociceptive effect of EEAP. The results revealed that naloxone reverses the antinociceptive effect of EEAP to some extent which impressed us to conceive that the opioid receptors may influence the central antinociceptive effect of EEAP through spinal and supraspinal mechanisms.

The acetic acid-induced writhing test is a relatively simple and rapid one but is considered with low specificity. In this
Table 3: Effect of EEAP on involvement of cyclic guanosine monophosphate (cGMP) pathway.

| Treatment (mg/Kg) | Writhing number (Mean ± SEM) | % Inhibition |
|------------------|-----------------------------|-------------|
| Control (0.1mL/mouse) | 73.30 ± 2.76 | - |
| MB (20) | 55.70 ± 4.94 | 24.01 |
| EEAP (50) | 49.20 ± 3.58* | 32.88 |
| EEAP (100) | 39.60 ± 4.21* | 45.98 |
| EEAP (200) | 23.60 ± 1.47* | 67.80 |
| MB (20) + EEAP (50) | 41.30 ± 2.31 | 43.66 |
| MB (20) + EEAP (100) | 28.90 ± 2.87 | 60.57 |
| MB (20) + EEAP (200) | 10.20 ± 0.82* | 86.08 |

Values are presented as the mean ± SEM (n = 5). EEAP = ethanol extract of A. pavonina; MB = methylene blue; * p < 0.001 compared with the control group (Dunnett’s test); a p < 0.05 compared with the EEAP 200 mg/kg group (Bonferroni’s test).

experiment, acetic acid acts as a potent inducer of writhing syndrome and causes algesia by increasing the level of proinflammatory mediators cyclooxygenase (COX), lipooxygenase (LOX), prostaglandins (PGs), histamine, serotonin, bradykinin, substance P, IL-1β, IL-8, and TNF-α in the peripheral tissue fluid, which then excite the peripheral nociceptive nerve endings [24, 25] resulting in inflammatory pain [26]. The results demonstrated that EEAP at the doses of 50, 100, and 200 mg/kg significantly reduced the number of writhing episodes in mice, indicating the inhibition of acetic acid-induced visceral nociception. This probably suggests that the inflammatory pathways might be the target of EEAP and that inhibitory action of EEAP may be due to the downregulation of synthesis, release, or retardation of action of the above mentioned endogenous substances or cytokines leading to an interference with the transduction of signals mediated through primary afferent nociceptors [27].

Oral administration of EEAP also significantly inhibited the noxious stimuli induced by L-glutamic acid in a dose-dependent manner. It has been reported that, among different excitatory amino acids, glutamate and aspartate play an important role in pain perception. In this study, intraplantar injection of glutamate produced the nociceptive response in mice. This phenomenon has been shown to be mediated through the action of glutamate on both N-methyl-D-aspartate (NMDA) and non-NMDA receptors in peripheral, spinal, and supraspinal sites [14]. Additionally, glutamate is also known to cause the release of proinflammatory mediators like nitric oxide (NO) and NO-related substances in both central and peripheral nervous systems [28]. Taking the above in consideration, it is conceivable that the antinociceptive activity of EEAP may be associated with its interaction with the glutamatergic system.

Finally, this study evaluated the antinociceptive activity of EEAP using formalin test. This test is a widely used model for studying pain and analgesia. Intraplantar injection of formalin in the paw was found to produce a biphasic nociception [29]. The sensation of this intensive pain seems to be due to the activation of primary afferent sensory neurons via specific and direct actions of the endogenous proinflammatory agents and cytokines on the Transient Receptor Potentials.
Potential Vanilloid-1 (TRPA-1), a member of the Transient Receptor Potential family (TRP) of cation channels that is highly expressed by a subset of C-Fiber nociceptors [30]. This is also in agreement with a previous study revealing that a biphasic release of PGE2 plays a vital role in formalin-induced nociceptive behavior [31]. In this study, EEAP caused significant inhibition of formalin-induced nociception in mice in a dose-dependent manner, both in neurogenic phase (early phase) and inflammatory phase (late phase), prompting us to consider that the antinociceptive activity of EEAP could be related to the suppression of proinflammatory mediators in the cyclooxygenase pathway.

To further investigate whether the antinociceptive action of EEAP involves the cGMP pathway, MB, a nonspecific inhibitor of NO/guanylyl cyclase, was used. NO, an essential bioregulatory molecule, has been shown to increase the level of cGMP by activating soluble guanylyl cyclase (sGC), leading to a wide range of physiological consequences including pain and analgesia [32]. The results demonstrated that pretreatment with MB, which inhibits peripheral NO production and sGC activation [32], significantly reduced the acetate acid-induced pain perception and also enhanced the antinociceptive activity of EEAP. This suggests that EEAP probably involves the NO-cGMP pathway in its antinociceptive mechanism in the prevailed experimental conditions.

In conclusion, the present study demonstrated the central and peripheral antinociceptive activity of ethanol extract of A. pavonina leaves against different animal models of acute nociception that can be related to the ethnomedical use of this plant leaves in treatment of different painful conditions. This study also suggests that the opioid receptors and cGMP pathway may contribute to the observed antinociceptive actions of EEAP. So, this multiplicity of mechanisms exhibited by the EEAP opens a great opportunity to develop multitarget drug candidates to treat pain and inflammation.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.
Acknowledgments

The authors are thankful to Professor Dr. Bidyut Kanti Datta, Chairman, Department of Pharmacy, Stamford University Bangladesh, for his permission to use the facilities of the Pharmacology Laboratory. The authors are also thankful to Protik Roy, Mahabub Ara Haque, and Md. Atikur Rahman for their help in animal handling.

References

[1] A. Coutaux, F. Adam, J.-C. Willer, and D. Le Bars, "Hyperalgesia and allodynia: peripheral mechanisms," Joint Bone Spine, vol. 72, no. 5, pp. 359–371, 2005.

[2] O. Obreja, P. K. Rathee, K. S. Lips, C. Distler, and M. Kress, "IL-1 beta potentiates heat-activated currents in rat sensory neurons: involvement of IL-1RI, tyrosine kinase, and protein kinase C," The FASEB Journal, vol. 16, no. 12, pp. 1497–1503, 2002.

[3] M. O. E. Hilário, M. T. Terreri, and C. A. Len, "Nonsteroidal anti-inflammatory drugs: cyclooxygenase 2 inhibitors," Jornal de Pediatria, vol. 82, no. 2, pp. S206–S212, 2006.

[4] A. Ghani, Medicinal Plant of Bangladesh with Chemical Constituents and Uses, Asiatic Society of Bangladesh, Dhaka, Bangladesh, 2nd edition, 2003.

[5] K. R. Kirtikar and B. D. Basu, Indian Medicinal Plants, International Book Distributors, New Delhi, India, 2nd edition, 1981.

[6] R. S. Mohammed, A. H. A. Zeid, E. A. El-Kashouy, A. A. Sleein, and D. A. Walry, "A new flavonol glycoside and biological activities of Adenanthera pavonina L. leaves," Natural Product Research, vol. 28, no. 5, pp. 282–289, 2014.

[7] S. K. Nigam, G. Misra, and C. R. Mitra, "Stigmasterol glycoside a constituent of Adenanthera pavonina seed and leaf," Planta Medica, vol. 23, no. 2, pp. 145–148, 1973.

[8] O. A. Olajide, C. A. Echianu, A. D. A. Adedapo, and J. M. Makinde, "Anti-inflammatory studies on Adenanthera pavonina seed extract," Inflammopharmacology, vol. 12, no. 2, pp. 197–202, 2004.

[9] O. J. Olakoyode, A. O. Emmanuel, A. O. Olajide, and J. M. Makinde, "Anticonvulsant and depressant activities of the seed extracts of Adnanthera pavonina," Journal of Natural Products, vol. 2, pp. 74–80, 2009.

[10] C. I. B. Walker, G. Trevisan, M. F. Rossato et al., "Antinociceptive activity of Mitribilis jalapa in mice," Journal of Ethnopharmacology, vol. 120, no. 2, pp. 169–175, 2008.

[11] B. Eddy and D. Leimbach, "Synthetic analogs: II. Dithienylbutinyl and dithienybutylamines," Journal of Pharmacology and Experimental Therapeutics, vol. 107, no. 3, pp. 385–393, 1953.

[12] F. E. D’Amour and D. L. Smith, "A method for determining loss of pain sensation," Journal of Pharmacology and Experimental Therapeutics, vol. 72, no. 1, pp. 74–79, 1941.

[13] M. R. Sulaiman, T. A. T. Mohamad, W. M. S. Mossadeq et al., "Antinociceptive activity of the essential oil of Zingiber zerumbet," Planta Medica, vol. 76, no. 2, pp. 107–112, 2010.

[14] A. Beirith, A. R. S. Santos, and J. B. Calixto, "Mechanisms underlying the nociception and paw oedema caused by injection of glutamate into the mouse paw," Brain Research, vol. 924, no. 2, pp. 219–228, 2002.

[15] A. R. S. Santos and J. B. Calixto, "Further evidence for the involvement of tachykinin receptor subtypes in formalin, and capsaicin models of pain in mice," Neuropeptides, vol. 31, no. 4, pp. 381–389, 1997.

[16] A. R. S. Santos, O. G. Miguel, R. A. Yunes, and J. B. Calixto, "Antinociceptive properties of the new alkaloid, cis-8, 10-di-N-propylpropobedol hydrochloride dihydrate isolated from Siphocampylus verticillatus: evidence for the mechanism of action," Journal of Pharmacology and Experimental Therapeutics, vol. 289, no. 1, pp. 417–426, 1999.

[17] M. Moniruzzaman, A. Ferdous, and S. Irin, "Evaluation of antinociceptive effect of ethanol extract of Hedyotis corymbosa Linn. whole plant in mice," Journal of Ethnopharmacology, vol. 161, pp. 82–85, 2015.

[18] M. Z. Imam and M. Moniruzzaman, "Antinociceptive effect of ethanol extract of leaves of Lamnea coromandelica," Journal of Ethnopharmacology, vol. 154, no. 1, pp. 109–115, 2014.

[19] C. A. Hiruma-Lima, J. S. Gracioso, E. J. B. Bighetti, L. G. Robineou, and A. R. M. Souza Brito, "The juice of fresh leaves of Boerhaavia diffusa L. (Nyctaginaceae) markedly reduces pain in mice," Journal of Ethnopharmacology, vol. 71, no. 1-2, pp. 267–274, 2000.

[20] K. Srinivasan, S. Muruganandan, J. Lal et al., "Antinociceptive and antipyretic activities of Pongamia pinnata leaves," Phytotherapy Research, vol. 17, no. 3, pp. 259–264, 2003.

[21] R. Arslan and N. Bektas, "Antinociceptive effect of methanol extract of Capparis ovata in mice," Pharmacological Biology, vol. 48, no. 10, pp. 1185–1190, 2010.

[22] Y. Jinsmaa, Y. Okada, Y. Tsuda et al., "Novel 2-tyrosine-containing pyrazinone opioid mimetic [Dmt1] endomorphin-2-mediated antinociception in the mouse," European Journal of Pharmacology, vol. 509, no. 1, pp. 37–42, 2005.

[23] Y. Jinsmaa, Y. Fujita, K. Shiotani et al., "Differentiation of opioid receptor preference by [Dmt1] endomorphin-2-mediated antinociception in the mouse," European Journal of Pharmacology, vol. 509, no. 1, pp. 37–42, 2005.

[24] P. P. Raj, "Pain mechanisms," in Pain Medicine: A Comprehensive Review, P. P. Raj, Ed., pp. 12–23, Mosby-Year Book, St. Louis, Mo, USA, 1st edition, 1996.

[25] Y. Ikeda, A. Ueno, H. Naraba, and S. Oh-Ishi, "Involvement of vanilloid receptor VR1 and prostanoids in the acid-induced writhing responses of mice," Life Sciences, vol. 69, no. 24, pp. 2911–2919, 2001.

[26] K. R. Bley, J. C. Hunter, R. M. Eglen, and J. A. M. Smith, "The role of IP prostaglandin receptors in inflammatory pain," Trends in Pharmacological Sciences, vol. 19, no. 4, pp. 141–147, 1998.

[27] H. L. Fields, "Analgesic drugs," in Pain, W. D. Day, Ed., p. 272, McGraw-Hill, New York, NY, USA, 1st edition, 1987.

[28] M. E. Fudytsus, "Glutamate receptors and nociception: implications for the drug treatment of pain," CNS Drugs, vol. 15, no. 1, pp. 29–58, 2001.

[29] A. Tjølsen, O.-G. Berge, S. Hunksaar, J. H. Rosland, and K. Hole, "The formalin test: an evaluation of the method," Pain, vol. 51, no. 1, pp. 5–17, 1992.

[30] C. R. McNamara, J. Mandel-Brehm, D. M. Bautista et al., "TRPA1 mediates formalin-induced pain," Journal of the National Academy of Sciences of the United States of America, vol. 104, no. 33, pp. 13525–13530, 2007.

[31] A. B. Malmberg and T. L. Yaksh, "Cyclooxygenase inhibition and the spinal release of prostaglandin E2 and amino acids evoked by paw formalin injection: a microdialysis study in unanesthetized rats," Journal of Neuroscience, vol. 15, no. 4, pp. 2768–2776, 1995.
[32] N. Abaclolu, B. Tunçtan, E. Akbulut, and I. Çaklcl, “Participation of the components of L-arginine/nitric oxide/cGMP cascade by chemically-induced abdominal constriction in the mouse,” *Life Sciences*, vol. 67, no. 10, pp. 1127–1137, 2000.

[33] J. Y. Xu, G. M. Pieper, and L. F. Tseng, “Activation of a NO-cyclic GMP system by NO donors potentiates β-endorphin-induced antinociception in the mouse,” *Pain*, vol. 63, no. 3, pp. 377–383, 1995.

[34] S. S. Ali, N. Kasoju, A. Luthra et al., “Indian medicinal herbs as sources of antioxidants,” *Food Research International*, vol. 41, no. 1, pp. 1–15, 2008.

[35] M. J. Alcaraz and J. R. S. Hoult, “Actions of flavonoids and the novel anti-inflammatory flavone, hypolaetin-8-glucoside, on prostaglandin biosynthesis and inactivation,” *Biochemical Pharmacology*, vol. 34, no. 14, pp. 2477–2482, 1985.

[36] D. Kempuraj, B. Madhappan, S. Christodoulou et al., “Flavonols inhibit proinflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cells,” *British Journal of Pharmacology*, vol. 145, no. 7, pp. 934–944, 2005.

[37] V. R. Ramprasath, P. Shanthi, and P. Sachdanandam, “Immuno-modulatory and anti-inflammatory effects of *Semecarpus anacardium* Linn. nut milk extract in experimental inflammatory conditions,” *Biological & Pharmaceutical Bulletin*, vol. 29, no. 4, pp. 693–700, 2006.

[38] E. K. Akkol, I. I. Tatli, and Z. S. Akdemir, “Antinociceptive and anti-inflammatory effects of saponin and iridoid glycosides from *Verbascum pterocalycinum* var. mutense Hub.-Mor,” *Verlag der Zeitschrift für Naturforschung*, vol. 62, no. 11-12, pp. 813–820, 2007.